Table 4.

Comparison of post-COVID-19 mucormycosis with historical cohort

	Historical cohort (n = 157)	Post-COVID-19 Mucormycosis cases (n = 11)	p-value
Demographic characteristics
Median (interquartile range) age, years	43 (32–50)	42 (33.5–50)	0.80
Male sex	133 (85%)	10 (90%)	1
Obesity	38 (24%)	5 (45.5%)	0.15
Thymoglobulin induction	129 (82%)	8 (73%)	0.42
History of antirejection therapy in past	26 (17%)	2 (18%)	1
History of diabetes*	29 (18%)	6 (54.5%)	0.01
Blood group distribution, n (%)
A	37 (24%)	4 (36%)	0.46
B	61 (39%)	4 (36%)	1
AB	7 (4%)	0 (0%)	1
O	52 (33%)	4 (36%)	1
Clinical symptoms on presentation, n (%)
Fever*	91 (58%)	11 (100%)	0.003
Cough*	77 (49%)	10 (90%)	0.009
Expectoration	50 (32%)	4 (36%)	0.74
Dyspnea	46 (29%)	4 (36%)	0.73
Diarrhea	37 (23%)	1 (9%)	0.45
No symptoms	7 (4%)	0 (0%)	1
Radiological chest abnormalities
Yes*	110 (70%)	11 (100%)	0.0001
No	47 (30%)	0 (0%)
COVID-19 severity
Asymptomatic	7 (4%)	0 (0%)	1
Mild	71 (45%)	8 (73%)	0.11
Moderate	48 (31%)	2 (18%)	0.50
Severe	31 (20%)	1 (9%)	0.69
Laboratory abnormalities, Median (interquartile range)
Lymphocytes %*	20 (12–26)	12 (10–18)	0.01
Neutrophil lymphocyte ratio*	3.85 (3.3–5.8)	7 (4.6–8.3)	0.0001
High-sensitivity C-reactive protein (mg/l)	49 (19–109)	44 (38–128)	0.81
Ferritin (ng/ml)	439 (196–998)	523 (423–1000)	0.64
D-dimer (μg/l)	1060 (540–2330)	1013 (497–1359)	0.90
Interleukin-6 (pg/ml) *	25 (14–82)	94.2 (66–108)	0.0001
Steroids use during COVID-19	79 (50.3%)	7 (63.6%)	0.53
Allograft dysfunction during COVID-19 course	79 (50%)	5 (45.5%)	1

*p-value defined as statistically significant if value was below 0.05; p-value was measured by Chi-square with Yate’s correction, Fisher test or T test as appropriate